Bio-Techne authorizes $500M share repurchase program, replacing prior 2022 authorization

BIO-TECHNE Corp

Board authorized up to $500M in common stock repurchases on April 30, 2025.
Replaces the prior $500M program approved February 2, 2022; no expiration date set.
Repurchases may be made in open market, private transactions, or block trades.
Management retains discretion based on market conditions, stock price, and capital needs.
Program intends to offset dilution from stock option exercises among other purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.